Kevin Dynan

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Martin Dennis, Gillian Mead, John Forbes et al. · The Lancet · 2018 · 276 citations · Full text

Moderately Elevated Plasma Homocysteine, Methylenetetrahydrofolate Reductase Genotype, and Risk for Stroke, Vascular Dementia, and Alzheimer Disease in Northern Ireland

Stephen P. McIlroy, Kevin Dynan, John T. Lawson et al. · Stroke · 2002 · 230 citations · Full text

Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: a case-control study

Shauna M. McCusker, Martin D. Curran, Kevin Dynan et al. · The Lancet · 2001 · 190 citations

Neurodegenerative Diseases, Alzheimer's Disease, Aging +14

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Rustam Al‐Shahi Salman, M. J. S. Dennis, PAG Sandercock et al. · The Lancet · 2019 · 188 citations · Full text

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Rustam Al‐Shahi Salman, David Minks, Dipayan Mitra et al. · The Lancet Neurology · 2019 · 88 citations · Full text